IL6 and COVID-19: Mechanistically, this increased thromboembolic risk can be explained by an upregulation of IL-6 production, especially in those with malignancy and/or severe forms of SARS-CoV-2 resulting in increased trans-signaling in endothelial cells (Fig. 1) that increases permeability resulting in edema, as well as showing signs of vasculitis [79] in post-COVID-19 patients which could lead to the development of thrombosis [5].